NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,897 | +3.5% | 11,580 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $6,661 | -45.5% | 11,580 | -33.3% | 0.00% | -50.0% |
| Q1 2023 | $12,211 | -68.9% | 17,370 | 0.0% | 0.00% | -71.4% |
| Q4 2022 | $39,256 | -29.9% | 17,370 | 0.0% | 0.01% | -41.7% |
| Q3 2022 | $56,000 | -15.2% | 17,370 | 0.0% | 0.01% | -14.3% |
| Q2 2022 | $66,000 | -29.8% | 17,370 | 0.0% | 0.01% | -12.5% |
| Q1 2022 | $94,000 | -60.0% | 17,370 | 0.0% | 0.02% | -61.0% |
| Q4 2021 | $235,000 | -24.7% | 17,370 | 0.0% | 0.04% | -18.0% |
| Q3 2021 | $312,000 | +4.7% | 17,370 | 0.0% | 0.05% | +6.4% |
| Q2 2021 | $298,000 | -33.3% | 17,370 | -25.0% | 0.05% | -39.7% |
| Q1 2021 | $447,000 | +13.5% | 23,160 | 0.0% | 0.08% | +27.9% |
| Q4 2020 | $394,000 | +2.6% | 23,160 | 0.0% | 0.06% | -17.6% |
| Q3 2020 | $384,000 | – | 23,160 | +115700.0% | 0.07% | – |
| Q2 2020 | $0 | – | 20 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |